Tricida Analyst & Investor Event
Please join Tricida for a comprehensive look at the company’s late stage drug candidate, veverimer, a potential first-in-class treatment for metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition that afflicts approximately 3 million adults in the US alone and can lead to muscle wasting, bone loss and progression of CKD.
Tuesday, October 15
8:00am - 11:30am
St. Regis Hotel
Two East 55th St, New York City
For more information or to RSVP, contact InvestorDay@tricida.com